Journey Medical Corp
DERM evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for DERM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · DERM
Journey Medical Corp is a commercial-stage pharmaceutical company founded in October 2014 that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions [sec_mda · as of 2026-08-12].
Key risk: Generic competition risk
BioSniper Score
Based on 5 of 6 signals
Market Cap
$210.8M
Cash Runway
68.8 moLead Asset
Accutane (Approved)Next Catalyst
Patent_Expiry · Oct 1, 2030Financial data as of Jun 30, 2026.
Tracking 6 pipeline candidates · 3 clinical trials · 4 catalysts · 5 FDA decisions for Journey Medical Corp.
Journey Medical Corp is a commercial-stage pharmaceutical company founded in October 2014 that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions [sec_mda · as of 2026-08-12].
- Commercial-stage pharmaceutical company founded in October 2014, focused on selling and marketing FDA-approved prescription products for dermatological conditions [sec_mda · as of 2026-08-12].
- As of 2026-06-30, the company reported cash & equivalents of $25.6M, total revenue of $18.5M, net income of -$0.3M, shareholders' equity of $31.9M, and total debt of $30.5M [sec].
- Current portfolio includes nine FDA-approved prescription drugs for dermatological conditions marketed in the U.S., with a majority of revenues deriving from branded, patent-protected products [sec_mda · as of 2026-08-12].
- The company relies on cash generated from product sales, a term loan credit facility with SWK Funding LLC, and an at-the-market sales program to fund operations and commercialization efforts [sec_mda · as of 2025-11-12].
What works
- The company has a portfolio of nine FDA-approved prescription drugs for dermatological conditions, with a majority of revenues from branded, patent-protected products, providing a diversified revenue base [sec_mda · as of 2026-08-12].
- Managed by experienced life science executives with a track record of creating value and bringing novel products to market [sec_mda · as of 2024-05-14].
- As of 2026-06-30, the company had positive shareholders' equity of $31.9M, indicating a solid equity base relative to total debt of $30.5M [sec].
What to weigh
- The company reported a net loss of $0.3M for the period ended 2026-06-30, reflecting ongoing challenges in achieving profitability [sec].
- A substantial portion of sales derive from products that may become subject to third-party generic competition, new competitor products, or market changes, posing revenue risk [sec · filed 2025-02-05].
- The company has total debt of $30.5M as of 2026-06-30, which may constrain financial flexibility and increase interest obligations [sec].
- SG&A expenses increased significantly, from $8.6M in Q3 2023 to $11.4M in Q3 2024, partly due to expansion of access platforms and launch efforts for Emrosi, indicating rising operational costs [sec · filed 2024-11-04].
From the filings
Quoted directly from source documents.
Company description and focus
“We are a commercial-stage pharmaceutical company founded in October 2014 that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions.”
SEC MD&A · August 12, 2026
Portfolio size and revenue source
“Our current portfolio includes nine FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. and a majority of our revenues derive from our branded, patent protected products.”
SEC MD&A · August 12, 2026
Risk of generic competition
“a substantial portion of our sales derive from products that may become subject to third-party generic competition, the introduction of new competitor products, or an increase in market”
SEC filings · February 5, 2025
SG&A expense increase
“Selling, general and administrative ("SG&A") expenses of $11.4 million for the three-month period ended September 30, 2024, compared to $8.6 million for the same period in 2023.”
SEC filings · November 4, 2024
Catalyst timeline
- 2030-10-01 · Patent_Expiry · ZILXI — Patent/Exclusivity Expiry: ZILXI — The patent or exclusivity for ZILXI is set to expire, which may open the product to generic competition.
- 2033-02-28 · Patent_Expiry · QBREXZA — Patent/Exclusivity Expiry: QBREXZA — The patent or exclusivity for QBREXZA is set to expire, potentially impacting market exclusivity.
- 2037-09-08 · Patent_Expiry · AMZEEQ — Patent/Exclusivity Expiry: AMZEEQ — The patent or exclusivity for AMZEEQ is set to expire, which could affect long-term revenue from this product.
- 2039-01-07 · Patent_Expiry · EMROSI — Patent/Exclusivity Expiry: EMROSI — The patent or exclusivity for EMROSI is set to expire, marking a key milestone for this recently launched product.
Risks & what to watch (4)›
Key risks
- Generic competition risk — Substantial portion of sales from products that may face third-party generic competition or new competitors [sec · filed 2025-02-05]
- Net loss and profitability — Reported net loss of $0.3M as of 2026-06-30, indicating ongoing profitability challenges [sec]
- High debt level — Total debt of $30.5M as of 2026-06-30 may limit financial flexibility and increase interest costs [sec]
- Rising operating expenses — SG&A expenses increased from $8.6M to $11.4M in Q3 2024 vs Q3 2023, partly due to launch efforts [sec · filed 2024-11-04]
What to watch
- Monitor revenue trends and net income trajectory, as the company reported a net loss of $0.3M as of 2026-06-30 [sec].
- Watch for updates on generic competition or market changes affecting key products, as a substantial portion of sales are from products that may face such risks [sec · filed 2025-02-05].
- Track the company's ability to manage debt of $30.5M and maintain liquidity, with cash & equivalents of $25.6M as of 2026-06-30 [sec].
- Observe the commercialization progress of Emrosi (Minocycline Hydrochloride Extended Release Capsules), which contributed to increased SG&A expenses [sec · filed 2024-11-04].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Journey Medical Corp through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Journey Medical Corp facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
68.8 months
D/E 2.06 · 0% dilution
Lead: Approved
6 candidates
4 upcoming, next in ~1493d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
68
Total value held
$51.8M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 2,164,160 | $10.1M |
| wasatch advisors lp | 2,133,370 | $10.0M |
| tang capital management llc | 1,610,000 | $7.6M |
| blackrock, inc. | 972,862 | $4.6M |
| j. goldman & co lp | 500,188 | $2.3M |
| geode capital management, llc | 463,202 | $2.2M |
| millennium management llc | 383,067 | $1.8M |
| summit financial, llc | 379,807 | $1.8M |
| ikarian capital, llc | 251,436 | $1.2M |
| renaissance technologies llc | 242,500 | $1.1M |
Showing top 10 of 68 institutional holders of Journey Medical Corp. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 24.5%
- Days to cover
- 17.6
- Shares short
- 3,674,135
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
DERM short interestGovernance
Frequently asked questions
What is the AI investment thesis for Journey Medical Corp?
Journey Medical Corp is a commercial-stage pharmaceutical company founded in October 2014 that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions [sec_mda · as of 2026-08-12].
What is Journey Medical Corp's lead drug candidate?
Journey Medical Corp's most advanced tracked candidate is Accutane (Approved) for Severe recalcitrant nodular acne.
What is Journey Medical Corp's next catalyst?
Journey Medical Corp's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: ZILXI" — expected October 1, 2030.
Who is the CEO of Journey Medical Corp?
Mr. Claude Maraoui is the chief executive officer of Journey Medical Corp (DERM).
Where is Journey Medical Corp headquartered?
Journey Medical Corp (DERM) is headquartered in Scottsdale, AZ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.